{"id":749478,"date":"2023-04-20T08:06:08","date_gmt":"2023-04-20T12:06:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/"},"modified":"2023-04-20T08:06:08","modified_gmt":"2023-04-20T12:06:08","slug":"aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/","title":{"rendered":"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>This agreement is a significant step for Aditxt as it expands its portfolio to include innovative therapies for infectious diseases; <\/i><\/li>\n<li><i>Aditxt will partner with global logistics leader Agility to address a growing global market need for effective antivirals<\/i><\/li>\n<\/ul>\n<p>RICHMOND, Va.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aditxt.com%2Fimmune-monitoring%2F&amp;esheet=53384578&amp;newsitemid=20230420005436&amp;lan=en-US&amp;anchor=Aditxt%2C%26%23174%3B+Inc.&amp;index=1&amp;md5=4f7c69e2330fca1c8e40028004f498ce\">Aditxt,\u00ae Inc.<\/a> (NASDAQ: ADTX) (\u201cAditxt\u201d or the \u201cCompany\u201d), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an asset purchase agreement with Cellvera, Ltd. (\u201dCellvera\u201d) that grants Aditxt (whether directly or in its recently formed wholly owned subsidiary Adivir, \u2122 Inc. (\u201cAdivir\u201d), a 50% ownership in G Response Aid FZE (\u201cGRA\u201d or \u201cGlobal Response Aid\u201d) with the other 50% owned by global logistics leader Agility, Inc. (KW: AGLTY) (\u201cAgility\u201d). The consideration for the transaction is (A) $24.5 million, comprised of: (i) the forgiveness of Aditxt\u2019s $14.5 million loan to Cellvera, and (ii) $10 million in cash, and (B) future royalties for 7 years. Together with Dr. Reddy\u2019s Laboratories, Ltd. (NYSE: RDY), GRA holds an exclusive, worldwide license for Avigan\u00ae 200mg, excluding Japan, China and Russia. In connection with the closing of this transaction, the Share Exchange Agreement previously entered as of December 28, 2021, between Cellvera Global Holdings, LLC f\/k\/a AiPharma Global Holdings, LLC (together with other affiliates and subsidiaries) and Aditxt and all other related agreements will be terminated.<\/p>\n<p>\nThe closing of the transaction remains subject to a number of conditions, including but not limited to, among others, approval by Aditxt\u2019s board of directors to enter into this transaction, financing of the purchase price, regulatory approvals for the transfer of shares, the resolution and satisfaction of all of Cellvera\u2019s creditors inclusive of those creditors who have initiated claims, and securing the rights to additional 3<sup>rd<\/sup>-party IP assets. No assurance can be given that all of the conditions to closing will be obtained or satisfied, or that the transaction will ultimately close.<\/p>\n<p>\n\u201cWe believe this acquisition has the potential to help drive Aditxt\u2019s strategic revenue and growth, as we move forward to help address a growing market need for more effective antivirals,\u201d said Amro Albanna, co-founder, chairman and CEO of Aditxt. \u201cWe are excited by the opportunity to play a key role in the development of Avigan in terms of clinical and commercial opportunities. We believe that Avigan can play a vital role in the treatment of a range of infectious diseases, due to the broad-spectrum nature of the molecule. Although we have only recently entered into the therapeutics market, our goal is to drive a paradigm shift in the treatment and prevention of infectious diseases globally through our newly formed subsidiary Adivir.\u201d<\/p>\n<p>\nGRA CEO Mitch Wilson said: \u201cWe\u2019re very excited about the partnership with Aditxt. Aditxt knows how to assess, develop, and commercialize promising innovations with a focus on immune health. Its expertise is critical in helping GRA bring Avigan to its full potential.\u201d<\/p>\n<p><b>About Aditxt, Inc.<\/b><\/p>\n<p>\nAditxt,\u00ae Inc. (NASDAQ: ADTX) is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. Aditxt\u2019s mission of \u201cMaking Promising Innovations Possible, Together\u201d is defined by our growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire our mission. Aditxt\u2019s diverse innovation portfolio includes: Adimune, Inc.\u2122, developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc.\u2122, focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta, Inc.\u2122, which offers personalized immune monitoring intended to be informative for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy.<\/p>\n<p>\nFor more information, visit the Company\u2019s websites at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aditxt.com%2F&amp;esheet=53384578&amp;newsitemid=20230420005436&amp;lan=en-US&amp;anchor=www.Aditxt.com&amp;index=2&amp;md5=106f09d735e26c60dbd8288b417e8103\">www.Aditxt.com<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.adimune.com%2F&amp;esheet=53384578&amp;newsitemid=20230420005436&amp;lan=en-US&amp;anchor=www.Adimune.com&amp;index=3&amp;md5=f57c17393ab6d39be06e66b954afd517\">www.Adimune.com<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pearsanta.com%2F&amp;esheet=53384578&amp;newsitemid=20230420005436&amp;lan=en-US&amp;anchor=www.Pearsanta.com&amp;index=4&amp;md5=7e13882198ef89e130b9dd899cdc723a\">www.Pearsanta.com<\/a>. Follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Faditxt%2Fmycompany%2F&amp;esheet=53384578&amp;newsitemid=20230420005436&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=7f9c1c8e4fa67d54c6936ac31c760cd5\">LinkedIn<\/a> for the latest company news.<\/p>\n<p><b>About Agility<\/b><\/p>\n<p>\nAgility is a global leader in supply chain services, infrastructure, and innovation with 45,000+ employees across six continents. The company is a pioneer in emerging markets and specializes in growing and scaling businesses. Agility\u2019s companies include the world\u2019s largest aviation services company (Menzies Aviation); a global fuel logistics business (TriStar); the market leader in logistics parks across the Middle East, South Asia, and Africa (Agility Logistics Parks); and a commercial real-estate company developing a $1.2 billion mega-mall in the UAE (UPAC). Other Agility companies: customs digitization services, remote-site infrastructure services, ecommerce-enablement and digital logistics. Agility invests in supply chain innovation, sustainability, and resilience, and has stakes in a growing portfolio of listed and non-listed companies looking to reshape their respective industries across various sectors.<\/p>\n<p>\nFor more information visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agility.com%2F&amp;esheet=53384578&amp;newsitemid=20230420005436&amp;lan=en-US&amp;anchor=www.agility.com&amp;index=6&amp;md5=9ef702c93ab0a112866d1d8e02141c6b\">www.agility.com<\/a>. Twitter: twitter.com\/agility. LinkedIn: linkedin.com\/company\/agility. YouTube: youtube.com\/user\/agilitycorp<\/p>\n<p><b>About Global Response Aid (GRA)<\/b><\/p>\n<p>\nGlobal Response Aid, based in Dubai, was established to address the market challenges created by the COVID-19 pandemic and other threats to public health. GRA delivers innovative, effective healthcare solutions through a range of pharmaceutical products and technology platforms. It works closely with governments, regulatory authorities, hospitals, clinics, healthcare providers, life sciences companies, NGOs and public institutions to develop strategies that allow them to tackle public health challenges.<\/p>\n<p>\nFor more information visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.globalresponseaid.com%2F&amp;esheet=53384578&amp;newsitemid=20230420005436&amp;lan=en-US&amp;anchor=www.globalresponseaid.com&amp;index=7&amp;md5=7722eaaaae88efd42d2ac9cdfb965bf8\">www.globalresponseaid.com<\/a><\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company&#8217;s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company&#8217;s ongoing and planned product and business development; the Company\u2019s ability to finance and execute on its strategic M&amp;A initiatives; the Company&#8217;s intellectual property position; the Company&#8217;s ability to develop commercial functions; expectations regarding product launch and revenue; the Company&#8217;s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company&#8217;s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230420005436\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230420005436\/en\/<\/a><\/span><\/p>\n<p>\nMedia and Investor Relations Contact:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@Aditxt.com\"><b>IR@Aditxt.com<\/b><\/a><\/p>\n<p><b>KEYWORDS:<\/b> Virginia United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Technology Public Relations\/Investor Relations Communications Software General Health Pharmaceutical Health Science Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan This agreement is a significant step for Aditxt as it expands its portfolio to include innovative therapies for infectious diseases; Aditxt will partner with global logistics leader Agility to address a growing global market need for effective antivirals RICHMOND, Va.&#8211;(BUSINESS WIRE)&#8211;Aditxt,\u00ae Inc. (NASDAQ: ADTX) (\u201cAditxt\u201d or the \u201cCompany\u201d), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an asset purchase agreement with Cellvera, Ltd. (\u201dCellvera\u201d) that grants Aditxt (whether directly or in its recently formed wholly owned subsidiary Adivir, \u2122 Inc. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-749478","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan This agreement is a significant step for Aditxt as it expands its portfolio to include innovative therapies for infectious diseases; Aditxt will partner with global logistics leader Agility to address a growing global market need for effective antivirals RICHMOND, Va.&#8211;(BUSINESS WIRE)&#8211;Aditxt,\u00ae Inc. (NASDAQ: ADTX) (\u201cAditxt\u201d or the \u201cCompany\u201d), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an asset purchase agreement with Cellvera, Ltd. (\u201dCellvera\u201d) that grants Aditxt (whether directly or in its recently formed wholly owned subsidiary Adivir, \u2122 Inc. &hellip; Continue reading &quot;Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-20T12:06:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan\",\"datePublished\":\"2023-04-20T12:06:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/\"},\"wordCount\":1181,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/\",\"name\":\"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-04-20T12:06:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/","og_locale":"en_US","og_type":"article","og_title":"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan - Market Newsdesk","og_description":"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan This agreement is a significant step for Aditxt as it expands its portfolio to include innovative therapies for infectious diseases; Aditxt will partner with global logistics leader Agility to address a growing global market need for effective antivirals RICHMOND, Va.&#8211;(BUSINESS WIRE)&#8211;Aditxt,\u00ae Inc. (NASDAQ: ADTX) (\u201cAditxt\u201d or the \u201cCompany\u201d), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, is pleased to announce the signing of an asset purchase agreement with Cellvera, Ltd. (\u201dCellvera\u201d) that grants Aditxt (whether directly or in its recently formed wholly owned subsidiary Adivir, \u2122 Inc. &hellip; Continue reading \"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-20T12:06:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan","datePublished":"2023-04-20T12:06:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/"},"wordCount":1181,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/","name":"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-04-20T12:06:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230420005436r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-signs-asset-purchase-agreement-to-acquire-fifty-percent-ownership-of-global-response-aid-with-rights-to-manufacture-and-market-broad-spectrum-antiviral-drug-avigan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid \u2013 with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=749478"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749478\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=749478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=749478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=749478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}